BRAF and melanoma: We treated three additional BRAFV600E-positive melanoma cell lines with vemurafenib and found that each and every persistent cell population (Figure 5f) displayed consistent upregulation of JUN and phospho-JUN upon short-term BRAF inhibitor exposure.